INVO Fertility (NASDAQ: IVF) is a medical technology and fertility services company specializing in in vitro fertilization (IVF) and assisted reproductive treatments. Established to broaden access to fertility care, the company develops innovative culture systems, diagnostic tools and clinical offerings designed to improve patient outcomes and reduce the complexity and cost traditionally associated with IVF. INVO Fertility’s proprietary device, the INVOcell® Intravaginal Culture (IVC) system, allows for embryo development within a patient’s body, offering an alternative to conventional laboratory incubation.
INVO Fertility’s product portfolio includes the INVOcell® device, complementary culture media, cryopreservation supplies and patient monitoring technologies. In addition to its core IVC system, the company provides training programs and partner support services for fertility clinics, helping practitioners integrate the INVOcell® platform into their treatment protocols. This integrated approach aims to streamline laboratory workflow, improve patient satisfaction and expand the availability of IVF services in lower-resource settings.
With its headquarters in Dania Beach, Florida, INVO Fertility serves a global customer base of reproductive clinics, hospitals and physician networks. The company has established distribution partnerships in North America, Latin America, Europe and select Asian markets, tailoring training curricula and regulatory support to meet regional requirements. Through collaboration with academic institutions and specialty fertility centers, INVO Fertility continues to explore clinical studies and real-world evidence to validate the safety and efficacy of its IVC technology.
INVO Fertility’s executive leadership team brings together experts in reproductive medicine, medical device commercialization and healthcare operations. The board of directors includes clinicians and industry veterans who guide corporate strategy, regulatory affairs and product development. Under this leadership, the company remains focused on advancing patient-centric fertility solutions, expanding global access to assisted reproductive technologies, and fostering long-term relationships with healthcare providers.
AI Generated. May Contain Errors.
Free IVF Stock Alerts